Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery
Diabetes Mellitus Type 2, Insulin Resistance
About this trial
This is an interventional basic science trial for Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing elective colorectal surgery for non-metastatic disease
- Type 2 diabetes mellitus with plasma level of glycosylated hemoglobin level (HbA(1c)) less than 10% indicating normal or moderate glycemic control
- Being capable of signing informed consent
- Accepting an epidural catheter for perioperative analgesia
Exclusion Criteria:
- American Society of Anesthesiologists (ASA) Physical Status classification system 4 with major cardiac disorders (severe arrhythmias, recent myocardial ischemia (MI), heart failure, uncontrolled hypertension)
- Hepatic disorders (liver failure, jaundice, metastatic disease), renal disorders (acute or chronic renal failure or on dialysis)
- Metabolic disorders (untreated hyperthyroidism, pyrexia, more than 10% weight loss over the preceding three months, plasma albumin concentration < 35g/l)
- Anemia (hemoglobin < 10 g/dl)
- Chemotherapy or radiotherapy during six months before surgery
- Inflammatory bowel disease or other inflammatory condition
- Pregnancy
- Previous spine surgery precluding placement of an epidural catheter.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intensified insulin group
Control group
Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.
Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses